Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Trial Profile

A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Malignant pleural effusion
  • Focus Adverse reactions
  • Acronyms MpeTK01
  • Sponsors Advantagene
  • Most Recent Events

    • 18 Oct 2017 Results assessing safety presented at the 18th World Conference on Lung Cancer.
    • 07 Jun 2016 Results assessing safety of AdV-tk theray presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 28 Oct 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top